

# [Corrigendum: immunoglobulin fc heterodimer platform technology: from design to ap...](https://assignbuster.com/corrigendum-immunoglobulin-fc-heterodimer-platform-technology-from-design-to-applications-in-therapeutic-antibodies-and-proteins/)

[Health & Medicine](https://assignbuster.com/essay-subjects/health-n-medicine/)

A corrigendum on

[Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
*by Ha J-H, Kim J-E, Kim Y-S. Front Immunol (2016) 7: 394. doi: 10. 3389/fimmu. 2016. 00394*](https://www.frontiersin.org/article/10.3389/fimmu.2016.00394/abstract)

In the original article, there was an error [wrong description on LY3164530 (Eli Lilly) antibody in the last paragraph of page 9 of original article].

A correction has been made to section “ HETERODIMERIC Fc-BASED ANTIBODIES IN DIVERSE FORMATS”, subsection “ Intact IgG Formats with Correct LC Association”, sixth Paragraph (line 8–12 of the sixth paragraph) (In the last paragraph of page 9 of original article):

An alternative approach for enforcing correct HC VH-CH1 –LC association includes introduction of a set of mutations at the heterodimeric VL–CL and VH–CH1 interface (18, 66, 67), similar to modification of the CH3 interface for the heterodimeric Fc design. In an ortho-Fab IgG approach (18), structure-based regional design introduced complementary mutations at the LC and HC VH-CH1 interface in only one Fab, without any changes being made to the other Fab (Figure 3). Zymeworks is currently developing intact IgG-format bsAbs generated by the combination of ortho-Fab IgG and ZW1 Fc technologies ( [http://www. zymeworks. com/](http://www.zymeworks.com/) ).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

## Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.